Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santen Pharma introduces Diquas Ophthalmic Solution 3% in Japan
Following the launch Inspire will receive a related milestone payment of $1.25m in the fourth quarter of 2010 and is also entitled to receive payments based upon a
Following the launch Inspire will receive a related milestone payment of $1.25m in the fourth quarter of 2010 and is also entitled to receive payments based upon a
In a regulatory filing Pfizer disclosed that Kindler will get an exit package that includes: $3.25m in cash bonus, a $1.8m cash ‘short-term incentive shift award,’ cash severance
Accovion provides study planning and management, clinical monitoring, pharmacovigilance including post-marketing safety, data management, biostatistics, statistical programming, medical writing and electronic publishing. Accovion chief operating officer Ivana Waller
Under the terms of the agreement, GSK will acquire Maxinutrition’s brands, including Maximuscle. GSK said the deal will extend its reach into wider categories, complementing its existing Nutritional
Teva‘s requests in this CP are based on the inability to establish acceptable ‘sameness’ of the active ingredients in glatiramer acetate, the complexity of the mechanism of action
Serodus has in-licensed RO1160367, a drug candidate ready to enter a clinical Phase II Proof-of-Concept study in heart failure. Under the Agreement, Serodus will receive the full preclinical
The data showed that the two antibodies plus docetaxel, given in the neoadjuvant setting prior to surgery, improved the rate of complete tumor disappearance in the breast by
Thelin will be withdrawn in regions where it is approved – the European Union, Canada and Australia, and the clinical studies of the drug will also be discontinued
The revised dosing recommendation extends the same dosing already approved for treatment-naive patients – Prezista, co-administered with ritonavir in combination with other antiretroviral agents and with food, once-daily
Actis will sell its 63% holding in Paras Pharma to RB. Reportedly, Sequoia Capital and the remaining shareholders, including Paras founder Girish Patel and his family, will also